FORM **NAMCS-CCS** (11-17-2006)

U.S. DEPARTMENT OF COMMERCE Economics and Statistics Administration U.S. CENSUS BUREAU ACTING AS DATA COLLECTION AGENT FOR THE U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics

NATIONAL AMBULATORY MEDICAL CARE SURVEY 2007 CERVICAL CANCER SCREENING SUPPLEMENT

NOTICE – Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA(0920-0234).

Assurance of Confidentiality - All information which would permit identification of an individual, a practice, or an establishment will be held confidential, will be used by persons engaged in and for the purpose of the survey and will not be disclosed or released to other persons or used for any other purpose without the consent of the individual or the establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m).

BACKGROUND INFORMATION										
0010 A.	Provider's name	0015	B.	Provider telephor		ea code	Number			
0020 C.	Provider's specialty (Mark (X) only ONE.)	0025	D.	Provider	's seria	Inumber				
	1 General/Family 2 Internal 3 OB/ 4 CHC Mid-level Practice Medicine GYN Provider									
0030 E.	Practice contact name	F.	Practice contact telephor		ea code	Number				
0040 G.	Census contact name	Census contact telephor		ea code	Number					
You h	The Centers for Disease Control and Prevention is conducting a special survey on cervical cancer screening performed in community health centers and private office settings. Please answer the following questions. We appreciate your time on this important public health concern. You have the option to complete this questionnaire on the Internet. Go to www.cdc.gov/nhamcs , select the link for the 2007 version of the Cervical Cancer Supplement, enter the User ID and Password displayed, and follow the instructions.									
User ID Password										
cerv	s your practice use any of the following methods to screetical cancer? (k (X) all that apply.	en for			Mark Annual	Evon.	Every 3 years	More than 3	No routine interval recom-	
0055 1 2	ventional Pap test (Definition – Smear spread on glass sli Yes – How often does your practice routinely screen wor using this method? No Unknown Continue with item 1b		d fixe	ed) →	 	2	3	4	mended 5	
b. Liqu	olutio	n) →	 - 1	2	3 🗆	4	5 🗌			
c. Othe	er – Specify 🗸				 					
0065 1 2	Yes – How often does your practice routinely screen wor this method?	nen u	sing		 	2	з□	4□	5□	
USCE	N S U S B U R E A U					•				

2.	Does this clinic perform colposcopy?	4a.	does your practice routinely order an HPV DNA test					
0050	1 ☐ Yes		to be performed on that sample (commonly called					
	2 □ No		reflex HPV DNA testing)? (An HPV DNA test may be					
	3 ☐ Unknown		run on the same liquid-based medium as the Pap test					
			or an HPV DNA test specimen may be collected at					
3a.	Does your practice ever order or collect the Human Papillomavirus (HPV) DNA test?	2005	the same time as the conventional Pap test.) 1 ☐ Yes – Go to item 4b					
0070	1 ☐ Yes – Go to item 3b	0085						
0070	$2\square$ No – SKIP to item 3c		2 No SKIP to item 5a					
	1		3 ☐ Unknown ∫ OKII To Rem 3a					
	3 Not aware of HPV DNA test SKIP to item 9							
	4 ☐ Unknown	L	For which harderline or abnormal Dan test regult would					
		, D.	For which borderline or abnormal Pap test result would your practice order or collect a reflex HPV DNA test?					
b.	Which of the following HPV DNA tests are ordered or		Mark (X) all that apply.					
	collected in your practice? Mark (X) all that apply.	0090	1 ☐ ASC-US (atypical squamous cells of undetermined					
0075	1 ☐ High risk (HR) HPV DNA test	0090	significance)					
	2 ☐ Low risk (LR) HPV DNA test		² ☐ ASC-H (atypical squamous cells of undetermined					
	3 ☐ Not aware there was a high risk or SKIP to		significance – cannot exclude high-grade					
	low risk HPV DNA test item 4a		intraepithelial lesion)					
	4 ☐ Type-specific HPV DNA test		3 ☐ LSIL (low-grade squamous intraepithelial lesion,					
	5 Unknown		encompassing mild dysplasia/CIN1)					
	,	-	4☐ HSIL (high-grade squamous intraepithelial lesion,					
c.	Why is the HPV DNA test not ordered or collected in		moderate dysplasia/CIN2, severe dysplasia/CIN3,					
	your practice? - Mark (X) all that apply.		and carcinoma in situ)					
0080			5 ☐ AGC (atypical glandular cells)					
0000	whom the HPV DNA test is indicated.							
		C.	For which patients does your practice usually order reflex					
	2 ☐ My practice uses other tests, procedures, or		HPV DNA testing? – Mark (X) all that apply.					
	examination methods to manage patients for whom	0095	1 ☐ Women under 30 years old					
	the HPV DNA test is indicated.	0000	2 ☐ Women 30 years old and over					
	₃☐ The patients in my practice have timely access to		•					
	colposcopy.		3 ☐ Other – Specify ⊋					
	According nationts' LIDV infection status is not a							
	4 Assessing patients' HPV infection status is not a priority at my practice.	5010						
	The labs affiliated with my practice do not offer the	5a.	Does your practice routinely recall patients to come back					
	HPV DNA test.		for a second sample collection for an HPV DNA test if					
	6☐ The health plans or health systems affiliated with		their Pap test is abnormal or borderline (recall testing)?					
	my practice do not recommend the HPV DNA test.	0100	1 ☐ Yes – <i>Go to item 5b</i>					
	The HDV DNA Is also as a second secon	0100	2 No					
	7 The HPV DNA test is not a reimbursed or covered service for most patients in my practice.		SKIP to item 6a on nage 3					
	service for most patients in my practice.		3 Unknown					
	8 ☐ Discussing cervical cancer screening in the context							
	of an STD is avoided in my practice.	b.	For which abnormal or borderline Pap test result would					
	Notifying or counsaling nationts about positive LDV		your practice recall a patient for an HPV DNA test?					
	9 Notifying or counseling patients about positive HPV DNA test results would take too much time.		Mark (X) all that apply.					
		0105	ASC-US (atypical squamous cells of					
	10 Notifying or counseling patients about positive HPV		undetermined significance)					
	DNA test results might make clinicians in my practice feel uncomfortable.		2 ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade					
	practice leer unconflictable.		intraepithelial lesion)					
	11 ☐ Notifying or counseling patients about positive HPV		3 LSIL (low-grade squamous intraepithelial lesion,					
	DNA test results might make patients in my		encompassing mild dysplasia/CIN1)					
	practice feel uncomfortable, angry, or upset.		4 ☐ HSIL (high-grade squamous intraepithelial lesion,					
			moderate dysplasia/CIN2, severe dysplasia/CIN3,					
	SKIP to item 7 on page 3.		and carcinoma in situ)					
			5 ☐ AGC (atypical glandular cells)					

Page 2 FORM NAMCS-CCS (11-17-2006)

6a.	6a. Does your practice routinely order or collect an HPV DNA test at the same time as the Pap test as part of routine cervical cancer screening (commonly called adjunct HPV testing or cotesting)?										
0110											
	2 No 3 Unknown SKIP to item 7										
b.	b. For which patients does your practice routinely order or collect an HPV DNA test along with the Pap test (commonly called adjunct HPV testing or cotesting)? <i>Mark (X) all that apply.</i>										
0115		Women under 30 ye									
	2 Women 30 years old and over 3 Women who request the										
		test for cervical canc screening	er								
		Women who request	the test to	check the	ir HPV infe	ction status					
	5	Other – <i>Specify</i> _✓									
5015											
_	0:									00 1	
7.	Given the following screening histories, when would your practice recommend that a woman between 30 and 60 years of age return for her next Pap test?										
Dr	ior D	on toot roculto	Current		For eac	ch of the fo	llowing scen	arios, mar	k (X) only	ONE for ea	ch row. Have no
	in pa (excl	ap test results ast 5 years uding current mal results)	HPV DNA test results	Current Pap test result	No follow-up needed	Less than 6 months	6 months to less than 1 year	1 year	2 years	3 years or more	experience with this type of patient or test
0120	(a)	Two consecutive normal Pap tests	Has not had test	Normal	1 🗌	2	3 🗆	4	5 🗌	6	7 🗆
0125	(b)	Two consecutive normal Pap tests	 Negative 	Normal	1	2	3 🗆	4 🗌	5 🗌	6	7
0130	(c)	Two consecutive normal Pap tests	 Positive	Normal	1 🗆	2	з□	4	5 🗆	6	7 🗆
0135	(d)	Has not had a Pap test	 Negative	Normal	1 🗆	2	3 🗆	4	5 🗌	6	7 🗆
0140	(e)	Has not had a Pap test	 Positive 	Normal	1 🗌	2	з□	4	5	6	7
0145	(f)	Abnormal Pap test	Negative	Normal	1 🗌	2	3 🗌	4	5 🗌	6 🗆	7 🗌
0150	(g)	Abnormal Pap test	Positive	Normal	1	2	3 🗆	4	5 🗌	6 🗆	7 🗌
QUESTIONS 8-10 ASK ABOUT THE HPV VACCINE											
8. How often does your practice use an HPV test to determine who should get the HPV vaccine? Mark (X) only one.											
1 ☐ Rarely or never 2 ☐ Sometimes											
з□ Usually											
$_4\Box$ Always or almost always $_5\Box$ Do not recommend the HPV vaccine – <i>SKIP to item 10.</i>											

FORM NAMCS-CCS (11-17-2006)

9.	As it relates to the HPV vaccine,									
	how often does your practice – Mark (X) only ONE for each row.	Rarely or never	Sometimes	Usually	Always or almost always	Unknown/not applicable/ Do not ask				
	a. Use the number of sexual partners to				-	Do not ask				
	determine who should get the HPV vaccine?	1 🗆	2	3 🗆	4 🗆	5 🗌				
	b. Perform a Pap test to determine who should get the HPV vaccine?	1 🗌	2	3 🗆	4 🗌	5 🗌				
	c. Recommend the HPV vaccine to females with a history of an abnormal Pap test result (ASC-US or higher)?	1	2	3 🗆	4 🗆	5 🔲				
	d. Recommend the HPV vaccine to females with a positive HPV test?	1 🗆	2	3□	4	5				
10.	 Will your practice's cervical cancer screening and management procedures change for females who have been fully vaccinated with the HPV vaccine? Yes No − SKIP to item 14 									
11.	How will your practice determine when to state cervical cancer screening for fully HPV vacce females?	vaccinate	age as non-HPV ed females –							
	Mark (X) all that apply.		Specify a	age ———	-					
			2□ At a later Specify a	age –						
		!	2 By onset of s	ŭ						
			How many ye							
		İ								
	4 ☐ Unknown									
12.	2. How often will your practice routinely screen for cervical									
	cancer among females that have been fully vaccinated 2 Every 2-3 years with the HPV vaccine? <i>Mark (X) one.</i> 3 Every 4-5 years									
	4 Greater than every 5 years									
		ا 5								
13.	Will your practice be using the HPV DNA test for managing abnormal cytology for females that have been fully vaccinated with the HPV vaccine? 1 □ Yes 2 □ No									
14.	Please indicate to what extent you agree, di with each statement. Please respond to both	Agree	Disagree	Unsure						
	There will be fewer numbers of abnormamong vaccinated females.	1 🗆	2	з 🗆						
	b. There will be fewer referrals for colpose vaccinated females.	1 🗆	2	з 🗆						
	5. The Centers for Disease Control and Prevention (CDC) funds state health departments to provide breast and cervical cancer screening services to low income women through the National Breast and Cervical Cancer Early Detection Program (Title XV). The state health departments contract out the screening services to physicians and other health care providers. Is this practice currently participating in this state or national screening program?									
0155										
	For purposes of this survey, which of the fo	llowing catego	,		• •					
0160	1 Physician 2 Physician assistance/ 3 Registered nurse 4 Other office staff Nurse practitioner/ Nurse midwife									

CLOSING STATEMENT

Thank you for completing this special survey. We appreciate your time and cooperation.

Page 4 FORM NAMCS-CCS (11-17-2008)